Dagfinn Albrechtsen

TL;DR: MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, although the 3 g dose was somewhat less well tolerated.

TL;DR: It is concluded that Scandinavian renal transplant recipients are at high risk of dying of HID, and future advances in long-term renal graft survival will depend largely on the success of preventing myocardial infarction and death in this patient population.

TL;DR: Although the incidence of first acute rejection was similar in CD and LD patients, it was successfully reversed by antirejection treatment in a higher percentage in LD patients and the estimated graft half-life was shorter in patients who had acute rejection episodes than those who did not.

TL;DR: Analysis of 3-year data for patient and graft survival, and safety in the MMF-treated patients indicates that MMF treatment not only results in a reduction of the incidence of acute rejections but also leads to reduction of late allograft loss.

TL;DR: The T cell depletion procedure provided a 43–74% recovery of non-T cells present in the Isopaque-Ficoll-isolated bone marrow mononuclear cell fraction and did not disturb the growth potential of stem cells, as assayed by hematopoietic stem cell assays.